Related references
Note: Only part of the references are listed.Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
C. Kent Osborne et al.
CLINICAL CANCER RESEARCH (2011)
Epidermal Growth Factor Receptor Expression in Breast Cancer Association With Biologic Phenotype and Clinical Outcomes
Mothaffar F. Rimawi et al.
CANCER (2010)
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
Massimo Cristofanilli et al.
CLINICAL CANCER RESEARCH (2010)
Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer
Anthony Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
Short Preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
Marta Guix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response
Jill Bayliss et al.
CLINICAL CANCER RESEARCH (2007)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
Ian E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
Suleiman Massarweh et al.
ENDOCRINE-RELATED CANCER (2006)
Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells
Robin L. Kilker et al.
CANCER RESEARCH (2006)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
Suleiman Massarweh et al.
CANCER RESEARCH (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
A Polychronis et al.
LANCET ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
CK Osborne et al.
BRITISH JOURNAL OF CANCER (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Using the gene ontology for microarray data mining: A comparison of methods and application to age effects in human prefrontal cortex
P Pavlidis et al.
NEUROCHEMICAL RESEARCH (2004)
EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast
A Lebeau et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection
C Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Regulation of the functional interaction between cyclin D1 and the estrogen receptor
J Lamb et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Molecular markers for predicting response to tamoxifen in breast cancer patients
DR Ciocca et al.
ENDOCRINE (2000)
Tumor characteristics and clinical outcome of elderly women with breast cancer
SG Diab et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
